Navigationshilfe

Hauptnavigation

Seiteninhalt

Publikationen

2014   2013   2012   2011   2010   2009   2008   2007

     2006   2005   2004   2003   2002   2001   2000

2011

Originalarbeiten | Original Articles

  1. Bertram L, Hampel H. The role of genetics for biomarker development in neurodegeneration. Prog Neurobiol. 2011; 95(4):501-4. Epub 2011 Oct 12.

  2. Broich K, Weiergräber M, Hampel H. Biomarkers in clinical trials for neurodegenerative diseases: Regulatory perspectives and requirements. Prog Neurobiol. 2011; 95(4):498-500. Epub 2011 Sep 16.

  3. Buerger K, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Blennow K, Moeller HJ, Teipel SJ, Ernst A, Bergmann A, Hampel H. Prediction of Alzheimer’s disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. J Clin Psychiat. 2011; 72(4):556-63. Epub 2010 Nov 2.

  4. Buschert VC, Friese U, Teipel SJ, Schneider P, Merensky W, Rujescu D, Möller HJ, Hampel H, Buerger K. Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer’s disease: A pilot study. J Alzheimers Dis. 2011; 25(4):679-94. Epub 2011 Apr 11.

  5. Conner KR, Beautrais AL, Brent DA, Conwell Y, Phillips MR, Schneider B. The next generation of psychological autopsy studies: Part I. Interview content. Suicide Life-Threat. 2011; 41(6):594-613. Epub 2011 Nov 3.

  6. Domschke K, Reif A, Weber H, Richter J, Hohoff C, Ohrmann P, Pedersen A, Bauer J, Suslow T, Kugel H, Heindel W, Baumann C, Klauke B, Jacob C, Maier W, Fritze J, Bandelow B, Krakowitzky P, Rothermundt M, Erhardt A, Binder EB, Holsboer F, Gerlach AL, Kircher T, Lang T, Alpers GW, Ströhle A, Fehm L, Gloster AT, Wittchen HU, Arolt V, Pauli P, Hamm A, Deckert J. Neuropeptide S receptor gene - converging evidence for a role in panic disorder. Mol Psychiatr. 2011; 16(9):938-48. Epub 2010 Jul 6.

  7. Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, Aasly J, Annesi G, Bozi M, Brighina L, Chartier-Harlin MC, Destée A, Ferrarese C, Ferraris A, Gibson JM, Gispert S, Hadjigeorgiou GM, Jasinska-Myga B, Klein C, Krüger R, Lambert JC, Lohmann K, van de Loo S, Loriot MA, Lynch T, Mellick GD, Mutez E, Nilsson C, Opala G, Puschmann A, Quattrone A, Sharma M, Silburn PA, Stefanis L, Uitti RJ, Valente EM, Vilariño-Güell C, Wirdefeldt K, Wszolek ZK, Xiromerisiou G, Maraganore DM, Farrer MJ; Genetic Epidemiology of Parkinson’s Disease (GEO-PD) Consortium. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol. 2011; 69(5):778-92. Epub 2011 Mar 9.

  8. Ewers M, Cheng X, Zhong Z, Nural HF, Walsh C, Meindl T, Teipel SJ, Buerger K, He P, Shen Y, Hampel H. Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer’s disease. J Alzheimers Dis. 2011; 25(2):373-81. Epub 2011 Apr 1.

  9. Ewers M, Frisoni GB, Teipel SJ, Grinberg LT, Amaro E Jr, Heinsen H, Thompson PM, Hampel H. Staging Alzheimer’s disease progression with multimodality neuroimaging. Prog Neurobiol. 2011; 95(4):535-46. Epub 2011 Jun 22.

  10. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer’s disease dementia. Trends Neurosci. 2011; 34(8):430-42. Epub 2011 Jun 20.

  11. Förster S, Buschert VC, Buchholz HG, Teipel SJ, Friese U, Zach C, la Fougere C, Rominger A, Drzezga A, Hampel H, Bartenstein P, Buerger K. Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer’s disease. J Alzheimers Dis. 2011; 25(4):695-706. Epub 2011 Apr 15.

  12. Förster S, Buschert VC, Teipel SJ, Friese U, Buchholz HG, Drzezga A, Hampel H, Bartenstein P, Buerger K. Effects of a 6-month cognitive intervention on brain metabolism in patients with amnestic MCI and mild Alzheimer’s disease. J Alzheimers Dis. 2011; 26(Suppl 3):337-48.

  13. Frings L, Klöppel S, Teipel S, Peters O, Frölich L, Pantel J, Schröder J, Gertz HJ, Arlt S, Heuser I, Kornhuber J, Wiltfang J, Maier W, Jessen F, Hampel H, Hüll M. Left anterior temporal lobe sustains naming in Alzheimer’s dementia and mild cognitive impairment. Curr Alzheimer Res. 2011; 8(8):893-901. Epub 2011 May 18.

  14. Frisoni GB, Hampel H, O’Brien JT, Ritchie K, Winblad B. Revised criteria for Alzheimer’s disease: what are the lessons for clinicians? Lancet Neurol. 2011; 10(7):598-601.

  15. Frodl T, Scheuerecker J, Schoepf V, Linn J, Koutsouleris N, Bokde ALW, Hampel H, Möller HJ, Brückmann H, Wiesmann M, Meisenzahl E. Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study. J Clin Psychiat. 2011; 72(4):448-57. Epub 2010 Sep 21.

  16. Fußer F, Linden DEJ, Rahm B, Hampel H, Haenschel C, Mayer JS. Common capacity-limited neural mechanisms of selective attention and spatial working memory encoding. Eur J Neurosci. 2011; 34(5):827-38. Epub 2011 Jul 22.

  17. Geser F, Malunda JA, Hurtig HI, Duda JE, Wenning GK, Gilman S, Low PA, Lee VMY, Trojanowski JQ. TDP-43 pathology occurs infrequently in multiple system atrophy. Neuropathol Appl Neurobiol. 2011; 37(4):358-65. Epub 2010 Oct 13.

  18. Geser F, Prvulovic D, O’Dwyer L, Hardiman O, Bede P, Bokde ALW, Trojanowski JQ, Hampel H. On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol. 2011; 95(4):649-62. Epub 2011 Sep 3.

  19. Haberstroh J, Neumeyer K, Krause K, Franzmann J, Pantel J. TANDEM: Communication training for informal caregivers of people with dementia. Aging Ment Health. 2011; 15(3):405-13.

  20. Hampel H, Prvulovic D, Teipel SJ, Bokde AL. Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer’s disease. Prog Neurobiol.2011; 95(4):570-8. Epub 2011 Jul 13.

  21. Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frölich L, Riepe MW, Dodel R, Leyhe T, Bertram L, Hoffmann W, Faltraco F; for the German task force on Alzheimer’s Disease (GTF-AD). The future of Alzheimer’s disease: The next 10 years. Prog Neurobiol. 2011; 95(4):718-28. Epub 2011 Nov 22.

  22. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B; for the Oxford Task Force Group. Biomarkers for Alzheimer’s disease therapeutic trials. Prog Neurobiol. 2011; 95(4):579-93. Epub 2010 Dec 2.

  23. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ERLC, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Rüther E, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011; 43(5):429-35. Epub 2011 Apr 3.

  24. Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL. Steps to standardization and validation of hippocampal volumetry as a biomarker for clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement. 2011; 7(4):474-85.e4.

  25. Jiang H, Hampel H, Prvulovic D, Wallin A, Blennow K, Li R, Shen Y. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease. Mol Neurodegener. 2011 Oct 6; 6(1):69.

  26. Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su’a M, Fagan AM, Holtzman DM, Morris JC; Alzheimer’s Disease Neuroimaging Initiative, Goate AM; Collaborators: Hampel H et al. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer’s disease. PLoS One. 2011; Feb 9;6(2):e15918.

  27. Klingberg S, Wölwer W, Engel C, Wittorf A, Herrlich J, Meisner C, Buchkremer G, Wiedemann G. Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. Schizophr Bull. 2011;37 Suppl 2:S98-110.

  28. Koppel J, Campagne F, Vingtdeux V, Dreses-Werringloer U, Ewers M, Rujescu D, Hampel H, Gordon ML, Christen E, Chapuis J, Greenwald BS, Davies P, Marambaud P. CALHM1 P86L polymorphism modulates CSF Aß levels in cognitively healthy individuals at risk for Alzheimer’s disease. Mol Med. 2011; 17(9-10):974-9. Epub 2011 May 24.

  29. Mattsson N, Andreasson U, Persson S, Albert M, Arai H, Batish D, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, O Forlenza, Frisoni GB, Galasko D, Galimberti D, Hampel H et al. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011; 7(4):386-95.e6.

  30. Mohr HM, Röder C, Zimmermann J, Hummel D, Negele A, Grabhorn R. Body image distortions in bulimia nervosa: investigating body size overestimation and body size satisfaction by fMRI. Neuroimage. 2011; 56(3):1822-31. Epub 2011 Feb 26.

  31. Nicotera P, Hampel H. Perspectives of worldwide translational biomarker research in neurodegenerative diseases. Prog Neurobiol. 2011; 95(4):496-7. Epub 2011 Jul 23.

  32. Norberg J, Graff C, Almkvist O, Ewers M, Frisoni GB, Frölich L, Hampel H, Jones RW, Kehoe PG, Lenoir H, Minthon L, Nobili F, Olde Rikkert M, Rigaud S, Scheltens P, Soininen H, Spiru L, Tsolaki M, Wahlund LO, Vellas B, Wilcock G, Elias-Sonnenschein LS, Verhey FR, Visser PJ. Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord. 2011; 32(2):135-42. Epub 2011 Sep 22.

  33. O’Dwyer L, Lamberton F, Bokde ALW, Ewers M, Faluyi YO, Tanner C, Mazoyer B, O’Neill D, Bartley M, Collins DR, Coughlan T, Prvulovic D, Hampel H. Using diffusion tensor imaging and mixed-effects models to investigate primary and secondary white matter degeneration in Alzheimer’s disease and mild cognitive impairment. J Alzheimers Dis. 2011; 26(4):667-82. Epub 2011 Jun 21.

  34. O’Dwyer L, Lamberton F, Bokde ALW, Ewers M, Faluyi YO, Tanner C, Mazoyer B, O’Neill D, Bartley M, Collins DR, Coughlan T, Prvulovic D, Hampel H. Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer’s disease. PLoS One. 2011; 6(6):e21745. Epub 2011 Jun 30.

  35. Oertel-Knöchel V, Bittner RA, Knöchel C, Prvulovic D, Hampel H. Discovery and development of integrative biological markers for schizophrenia. Prog Neurobiol. 2011; 95(4):686-702. Epub 2011 Jun 6.

  36. Oertel-Knöchel V, Linden DE. Cerebral asymmetry in schizophrenia. Neuroscientist. 2011; 17(5):456-67. Epub 2011 Apr 25.

  37. Olsson B, Zetterberg H, Hampel H, Blennow K. Biomarker-based dissection of neurodegenerative diseases. Prog Neurobiol. 2011; 95(4):520-34. Epub 2011 Apr 16.

  38. Prvulovic D, Bokde AL, Faltraco F, Hampel H. Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer’s disease. Prog Neurobiol. 2011; 95(4):557-69. Epub 2011 Jun 22.

  39. Prvulovic D, Hampel H. Ethical considerations of biomarker use in neurodegenerative diseases – A case study of Alzheimer’s disease. Prog Neurobiol. 2011; 95(4):517-9. Epub 2011 Nov 22.

  40. Röder CH, Mohr H, Linden DEJ. Retention of identity versus expression of emotional faces differs in the recruitment of limbic areas. Neuropsychologia. 2011; 49(3):444-53. Epub 2010 Dec 4.

  41. Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Ferraris A, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, van de Loo S, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Farrer MJ; Genetic Epidemiology Of Parkinson’s Disease (GEO-PD) Consortium. Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case-control study. Lancet Neurol. 2011; 10(10):898-908. Epub 2011 Aug 30. Erratum in: Lancet Neurol. 2011; 10(10):870.

  42. Schneider B, Baumert J, Schneider A, Marten-Mittag B, Meisinger C, Erazo N, Hammer GP, Ladwig KH. The effect of risky alcohol use and smoking on suicide risk: findings from the German MONICA/KORA-Augsburg Cohort Study. Soc Psychiatry Psychiatr Epidemiol. 2011; 46(11):1127-32. Epub 2010 Sep 21.

  43. Schneider B, Fritze J, Georgi K, Grebner K. Finden suizidale Suchtkranke Hilfsangebote im Internet? [Do individuals with substance use disorders find information for crisis intervention and suicide prevention resources on the Internet?] Nervenarzt. 2011; 82(7):859-65. Epub 2010 Apr 10.

  44. Schneider B, Grebner K, Schnabel A, Georgi K. Is the emotional response of survivors dependent on the consequences of the suicide and the support received? Crisis. 2011; 32(4):186-93. Epub 2011 Jun 30.

  45. Schneider B, Grebner K, Schnabel A, Georgi K. Do suicides’ characteristics influence survivors’ emotions? Suicide Life Threat Behav. 2011;41(2):117-25.

  46. Schneider B, Grebner K, Schnabel A, Hampel H, Georgi K, Seidler A. Impact of employment status and work-related factors on risk of completed suicide A case-control psychological autopsy study. Psychiatry Res. 2011; 190(2-3):265-70. Epub 2011 Sep 3.

  47. Schneider B, Prvulovic D, Oertel-Knöchel V, Knöchel C, Reinke B, Grexa M, Weber B, Hampel H. Biomarkers for major depression and its delineation from neurodegenerative disorders. Prog Neurobiol. 2011; 95(4):703-17. Epub 2011 Aug 12.

  48. Schneider P, Buerger K, Teipel S, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Rujescu D, Moeller HJ, Zetterberg H, Blennow K, Ernst A, Bergmann A, Hampel H. Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer’s disease in MR-proANP stratified subjects with mild cognitive impairment. Biol Psychiat. 2011; 70(2):145-51. Epub 2011 Mar 31.

  49. Schüler-Schneider A, Schneider B, Hillert A. Burnout als Krankheitskonzept [Burnout as a disease category]. Psychiat Prax. 2011; 38(7):320-2.

  50. Sikkes SA, Visser PJ, Knol DL, de Lange-de Klerk ES, Tsolaki M, Frisoni GB, Nobili F, Spiru L, Rigaud AS, Frölich L, Rikkert MO, Soininen H, Touchon J, Wilcock G, Boada M, Hampel H, Bullock R, Vellas B, Pijnenburg YA, Scheltens P, Verhey FR, Uitdehaag BM. Do instrumental activities of daily living predict dementia at 1- and 2-year follow-up? Findings from the development of screening guidelines and diagnostic criteria for predementia Alzheimer’s disease study. J Am Geriatr Soc. 2011; 59(12):2273-81.

  51. Singer OC, Conrad F, Jahnke K, Hattingen E, Auer H, Steinmetz H. Severe meningoencephalomyelitis due to CNS-Toxocarosis. J Neurol. 2011; 258(4):696-8. Epub 2010 Nov 5.

  52. Teipel SJ, Buchert R, Thome J, Hampel H, Pahnke J. Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Prog Neurobiol. 2011; 95(4):547-56. Epub 2011 May 12.

  53. Teipel SJ, Meindl T, Grinberg L, Grothe M, Cantero JL, Reiser MF, Möller HJ, Heinsen H, Hampel H. The cholinergic system in mild cognitive impairment and Alzheimer’s disease: An in vivo MRI and DTI study. Hum Brain Mapp. 2011; 32(9):1349-62. Epub 2010 Jul 29.

  54. Teipel SJ, Peters O, Heuser I, Jessen F, Maier W, Froelich L, Arlt S, Hüll M, Gertz HJ, Kornhuber J, Wiltfang J, Thome J, Rienhoff O, Meindl T, Hampel H, Grothe M. Atrophy outcomes in multicentre clinical trials on Alzheimer’s disease: Effect of different processing and analysis approaches on sample sizes. World J Biol Psychia. 2011; 12(S1):109-13.

  55. Teipel SJ, Reuter S, Stieltjes B, Acosta-Cabronero J, Ernemann U, Fellgiebel A, Filippi M, Frisoni G, Hentschel F, Jessen F, Klöppel S, Meindl T, Pouwels PJ, Hauenstein KH, Hampel H. Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study. Psychiat Res-Neuroim. 2011; 194(3):363-71. Epub 2011 Nov 9.

  56. Trojanowski JQ, Hampel H. Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. Prog Neurobiol. 2011; 95(4):491-5. Epub 2011 Jul 23.

  57. Varges D, Jung K, Gawinecka J, Heinemann U, Schmitz M, von Ahsen N, Krasnianski A, Armstrong VW, Zerr I. Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer’s disease. J Alzheimers Dis. 2011; 23(4):717-26.

  58. Vass R, Ashbridge E, Geser F, Hu WT, Grossman M, Clay-Falcone D, Elman L, McCluskey L, Lee VMY, Van Deerlin VM, Trojanowski JQ, Chen-Plotkin AS. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol. 2011; 121(3):373-80. Epub 2010 Nov 23.

  59. Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer’s disease: an Eu-US task force report. Prog Neurobiol. 2011; 95(4):594-600. Epub 2011 Sep 10.

  60. Wagner M, Wolf S, Reischies F, Daerr M, Wolfsgruber S, Jessen F, Popp J, Maier W, Hüll M, Frölich L, Hampel H, Perneczky R, Peters O, Jahn H, Luckhaus C, Gertz HJ, Schröder J, Pantel J, Lewczuk P, Kornhuber J, Wiltfang  J. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer’s disease. Neurology. 2011. (accepted)

 

Reviews

  1. Güttgemanns J, Büch A, Sevecke K, Döpfner M, Lehmkuhl G, Herrlich J, Müller K, Wiedemann G, Klingberg S, Bechdolf A. [Early onset psychosis: rationale and concept of a cognitive-behavioral intervention]. Fortschr Neurol Psychiatr. 2011;79(9):524-30.

  2. Noelker C, Hampel H, Dodel R. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. Mol Diagn Ther. 2011; 15(2):83-102.

  3. Prvulovic P, Hampel H. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer’s disease. Clin Chem Lab Med. 2011; 49(3):364-77. Epub 2011 Feb 23.

 

Buch | Book

  1. Hampel H, Trojanowski JQ (Hg.). Biological Markers for Neurodegenerative Diseases. Progess in Neurobiology, Special Issue (vol. 95, no. 4). Elsevier, Amsterdam, 2011, pp. 491-728.

 

Buchbeiträge | Book Chapters

  1. Buschert VC, Bokde ALW, Hampel H. Kognitionsbezogene Interventionen bei leichter kognitiver Beeinträchtigung. In: Demenz psychosozial behandeln. Psychosoziale Interventionen bei Demenz in Praxis und Forschung (Hg.: Haberstroh J, Pantel J). AKA Verlag, Heidelberg, 2011, 79-90.

  2. Hampel H, Pantel J. Demenz. In: Psychiatrie, Psychosomatik, Psychotherapie (Hg.: Möller HJ, Laux G, Kapfhammer HP). 4. Auflage, Springer Verlag, Berlin, Heidelberg, New York, 2011, Bd. 2, 31-110.

  3. Hampel H, Prvulovic D. Diagnostik demenzieller Syndrome. In: Therapie psychischer Erkrankungen. State of the Art 2011/2012 (Hg.: Voderholzer U, Hohagen F). 7. Auflage, Urban & Fischer/Elsevier, München, 2011, 2-9.

  4. Roth I, Matura S, Pantel J. Psychoedukation und Training zur Alltags- und Krankheitsbewältigung. In: Demenz psychosozial behandeln. Psychosoziale Interventionen bei Demenz in Praxis und Forschung (Hg.: Haberstroh J, Pantel J). AKA Verlag, Heidelberg, 2011, 91-98.

  5. Schneider B, Grebner K. Information for crisis intervention and suicide prevention resources for individuals with substance use disorders on the Internet. In: Internet and suicide (Hg.: Sher L, Vilens A). Nova Science Publishers, Hauppauge NY, 2011, 243-253.

 

 

geändert am 13. Mai 2014  E-Mail: Kontaktpsychiatrie@kgu.de

|

| Zur Navigationshilfe
empty

Seitenabschlussleiste


Druckversion: 13. Mai 2014, 10:33
http://www.uni-frankfurt.de/fb/fb16/fachklinik/psychiatrie/publikationen/pub_2011.html